Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of inotuzumab ozogamicin in pediatric CD22-positive relapsed/refractory B-cell malignancies
MOH_2017-07-20_000657Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) and B-cell malignancy (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary endpoints not reported. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)B-cell malignancy
Beyond the preview
Go deeper on MOH_2017-07-20_000657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-20_000657.